Riskpilot← Back to searchSign inGet full accessARXX Therapeutics ApS
APSActiveCVR 40868151Hørkær 12AManufacture of pharmaceutical preparations · NACE 2120Est. 20193 employees
Revenue 2025
DKK 3,7M
+44% vs 2024
EBITDA margin
24.4%
+499% vs 2024
Equity ratio
87.6%
Financial strength
Net profit 2025
DKK 707K
+505% vs 2024
| Revenue | DKK 3,7M | +44% |
| EBITDA | DKK 912K | +499% |
| Net profit | DKK 707K | +505% |
| Total assets | DKK 1,9M | +43% |
| Equity | DKK 1,7M | +72% |
| Employees | 3 | — |
Legal name
ARXX Therapeutics ApS
CVR number
40868151
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. oktober 2019
Share capital
DKK 100.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af den samlede direktion
Company purpose
Selskabets formål er at udvikle, markedsføre og sælge lægemidler samt al virksomhed, som efter direktionens skøn er beslægtet hermed
Address
Hørkær 12A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.129 | 2.397 | 5.790 | 2.791 | 2.608 | 3.744 |
| Staff expenses | -1.595 | -1.621 | -1.631 | -1.456 | -1.972 | -1.728 |
| EBITDA | 0 | 33 | 455 | 236 | 152 | 912 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | 33 | 455 | 236 | 152 | 912 |
| Net financials | -3 | 44 | 196 | 39 | 1 | -5 |
| Profit before tax | -3 | 77 | 651 | 275 | 153 | 907 |
| Tax | -0 | -0 | 144 | 6 | 36 | 200 |
| Net profit | -3 | 77 | 507 | 270 | 117 | 707 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 419 | 729 | 1.173 | 1.221 | 1.351 | 1.927 |
| Equity | 97 | 177 | 596 | 865 | 982 | 1.689 |
| Long-term debt | 0 | 0 | 0 | 61 | 10 | 164 |
| Short-term debt | 322 | 551 | 577 | 294 | 359 | 74 |
| Total debt | 322 | 551 | 577 | 355 | 369 | 238 |
EBITDA margin
24.4%
This company
15.8%
Market median
+54% vs market
20202025
Equity ratio
87.6%
This company
38.2%
Market median
+129% vs market
20202025
Return on equity
41.8%
This company
18.4%
Market median
+127% vs market
20202025
Net profit margin
18.9%
This company
8.1%
Market median
+133% vs market
20202025
Asset turnover
1.94×
This company
1.12×
Market median
+73% vs market
20202025
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20202025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BA Management | Management | 2025 | — | — |
JH Management | Management | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ARXX Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Berte Aagot Hedding Poulsson | Management | 0 companies |
| Jonas Hallén | Management | 0 companies |
| Farzad Abdi-Dezfuli | Board of Directors | 0 companies |
| Susanne Stuffers | Chairman | 0 companies |